According to Revance Therapeutics's latest financial reports the company's current earnings (TTM) are -$0.31 B. In 2022 the company made an earning of -$0.34 B a decrease over its 2021 earnings that were of -$0.28 B.The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Year | Earnings | Change |
---|---|---|
2023 (TTM) | -$0.31 B | -10.29% |
2022 | -$0.34 B | 23.35% |
2021 | -$0.28 B | 2.03% |
2020 | -$0.27 B | 69.08% |
2019 | -$0.16 B | 14.27% |
2018 | -$0.14 B | 16.14% |
2017 | -$0.13 B | 36.22% |
2016 | -$88.19 M | 22% |
2015 | -$72.29 M | 38.36% |
2014 | -$52.25 M | 40.12% |
2013 | -$37.29 M |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $21.36 B | -7,119.68% | ๐บ๐ธ USA |
Biogen BIIB | $1.32 B | -534.82% | ๐บ๐ธ USA |
MediciNova MNOV | -$8.57 M | -97.18% | ๐บ๐ธ USA |